Q3 FY2026 · ended Sep 30, 2026 · Revenue $716.00M, +8.5% YoY · Filed Oct 22, 2026
Medpace Holdings, Inc. (MEDP) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $716.0 million and net income of $137.5 million. Free cash flow was $196.4 million. As of Sep 30, 2026 it held $705.3 million in cash and investments and $171.5 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MEDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1668397
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $716.0M | $707.3M | $706.6M | $708.5M | $659.9M |
| Operating income | $165.5M | $146.8M | $141.5M | $153.3M | $141.8M |
| Net income | $137.5M | $121.4M | $123.9M | $135.1M | $111.1M |
| Diluted EPS | $4.84 | $4.25 | $4.28 | $4.66 | $3.86 |
| Operating cash flow | $216.6M | $162.0M | $151.8M | $192.7M | $246.2M |
| Free cash flow | $196.4M | $138.1M | $145.0M | $188.1M | $235.5M |
| Total assets | $2.3B | $2.1B | $2.1B | $2.0B | $1.8B |
| Total liabilities | $1.7B | $1.6B | $1.5B | $1.5B | $1.5B |
| Stockholders' equity | $584.9M | $433.9M | $598.3M | $459.1M | $293.6M |
| Cash and investments | $705.3M | $502.7M | $652.7M | $497.0M | $285.4M |
| Total debt | $171.5M | $144.1M | $146.1M | $136.9M | $144.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 22, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 4, 2026 | Jun 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 19, 2026 | May 15, 2026 |
All 930 Medpace Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.